Citations

Mayo Clinic

Clear

763 citation(s) found for "Bähr, Oliver".

Dissecting the biology of gliomagenesis: Evaluating the interaction between IDH tumor mutation and germline variants
Kosel, Matthew , Decker, Paul A. , Kollmeyer, Thomas M. , Shurtz, Anne K., Molinaro, Annette M. , Moassefi, Mana , Wrensch, Margaret , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Vaubel, Rachel A, Jenkins, RB , Eckel-Passow, Jeanette E , Kollmeyer, Thomas , Decker, Paul A. , Drucker, Kristen , Molinaro, Annette M. , Conte, Gian Marco , Moassefi, Mana , Erickson, Bradley J. , Wiencke, John K. , Francis, Stephen , Burns, Terry C. , Vaubel, Rachael A. , Lachance, Daniel Honore , Tobin, W. Oliver

Neuro-Oncology Advances | July 8, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf147 | PMID 40709013 Get It

Abstract Background The CCDC26 germline variant rs55705857 is causal for development of IDH mutant (IDHmut) adult glioma. However, ~60% of IDHmut patients do not carry the rs55705857 risk allele. We aimed to identify variants associated with developing IDHmut glioma among patients that do not have the rs55705857 risk allele and to further understand development of IDHwt glioma. Methods We used three datasets that included 1216 IDHmut and 1442 IDHwt glioma patients and a case–case design to perform genome-wide association (GWAS) analyses comparing IDHmut versus IDHwt glioma. Analyses were performed overall and stratified by rs55705857 genotype and sex. Multivariable logistic regression and regression trees were used to develop models to predict IDH status using germline variants, age, and contrast enhancement on MRI. Results Three regions were identified comparing IDHmut versus IDHwt: rs55705857 (meta P-value [P] = 1.35 × 10−43), PHLDB1 (rs7125115, P = 3.46 × 10−17), and D2HGDH (rs71430382, P = 2.43 × 10−12). When analyzing only patients that do not have the rs55705857 risk allele, PHLDB1 (rs7125115, P = 1.73 × 10−13) and D2HGDH (rs71430382, P = 8.86 × 10−10) were identified. Among patients who have the rs55705857 risk allele, four variants between ROBO1 and ROBO2 (rs4680975, P = 4.65 × 10−7) increased the likelihood of having an IDHwt tumor. Tumor expression of ROBO1 was associated with rs4680975 genotype in IDHwt patients that have the rs55705857 risk allele (P = 0.034). Multivariable logistic analysis demonstrated that rs55705857, rs71430382 (D2HGDH), and age predicted IDH mutation status. Conclusions To understand the development of adult glioma, we demonstrate that D2HGDH and PHLDB1 should be prioritized for functional studies in IDHmut tumors. The ROBO1 region warrants further investigation in IDHwt tumors.
The contemporary management of prostate cancer
Chakrabarti, Deep , Albertsen, Peter C. , Adkins, Aidan, Kishan, Amar U. , Murthy, Vedang, Parker, Chris, Pathmanathan, Angela, Reid, Alison , Sartor, Oliver, Walz, Jochen , Tree, Alison , Walz, Jochen , Tree, Alison C , As, Nicholas van

CA: A Cancer Journal for Clinicians | June 27, 2025 | Volume: 75 | Issue: 6 | Pages: 552-586

10.3322/caac.70020 | PMID 40572035 Get It

Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden. The last three decades have seen rapid developments in the diagnostic and therapeutic landscape of prostate cancer, including multiparametric magnetic resonance imaging, positron emission tomography, robotic surgery, image‐guided hypofractionated and stereotactic radiotherapy, novel anti‐androgens and radioligand therapies. Prostate cancer is unique in that not everyone with a diagnosis needs treatment, and active surveillance is the preferred option for some. This review discusses the contemporary management of all stages of prostate cancer in the light of these modern developments, enabling holistic individualization of treatment, and describes the promise of future research to further improve outcomes.
Developing and sustaining inclusive language in biomedical informatics communications: an AMIA Board of Directors endorsed paper on the Inclusive Language and Context Style Guidelines
Walk, Oliver Bear Don’t, Haldar, Shefali , Wei, Duo, Huang, Hu , Keloth, Vipina K. , Leung, Tiffany I. , Desai, Pooja , Korngiebel, Diane M. , Wiley, Laura K. , Ogunyemi, Omolola , Dirks, Lisa G. , Kronk, Clair , Martin, Krista, Anand, Tara V. , Volpe, Salvatore G, Yung, Nathan , Lucero, Robert , Bright, Tiffani J , Walk, Oliver J. Bear Don’t , Fan, Jungwei , Keloth, Vipina K , Desai, Pooja , Grossman Liu, Lisa , Pichon, Adrienne , Subbian, Vignesh , Solomonides, Anthony E , Wiley, Laura K , Ogunyemi, Omolola , Iott, Bradley , Kronk, Clair , Foraker, Randi , Anand, Tara , Bear Don't Walk Iv, Oliver J , Rivera, Rebecca L. , Fan, Jungwei , Subbian, Vignesh , Solomonides, Anthony , Jackson, Gretchen Purcell , Dankwa‐Mullan, Irene , Everhart, Avery , Parker, Andrea G. , Foraker, Randi E. , Volpe, Salvatore G, Rizvi, Rubina F

Journal of the American Medical Informatics Association | June 16, 2025 | Volume: 32 | Issue: 8 | Pages: 1380-1387

10.1093/jamia/ocaf096 | PMID 40523007 Get It

Abstract Objectives In 2023, AMIA’s Inclusive Language and Context Style Guidelines (the “Guidelines”) were approved by the Board of Directors and made a publicly available resource. This work began in 2021 through AMIA’s DEI Task Force and subsequent DEI Committee; many members provided input, feedback, and time to create the Guidelines. In this paper, the authors provide a transparent account of the origin, development, contents, and dissemination of the Guidelines and share plans for their future development and use. Materials and Methods Our approach to drafting, refining, and distributing the Guidelines included consulting existing language guides, AMIA member reviews, external expert reviews, webinars, and workshops. Through an iterative approach to drafting and refining the Guidelines, the authors consulted relevant language guidelines and many experts throughout and beyond the AMIA community. Results The Inclusive Language Context Guidelines were formally approved by the AMIA Board of Directors on February 15, 2023. The Guidelines included four principles to be considered in scientific communications: Plurality, Precision, Transparency, and Destigmatization. Discussion A moment of vulnerability where an AMIA member raised concerns about the use of harmful language during a presentation resulted in the creation of a principled approach to support inclusive language within biomedical and health informatics communications. We envision that the Guidelines will support health equity by challenging dominant public narratives around health, fostering stronger interdisciplinary collaboration and critical thinking about the impact of language, and creating a more welcoming environment for the broader AMIA community. This work could not have been completed without the support of many AMIA members and other researchers in biomedical and health informatics. The Guidelines are a living document that will continue to be updated with input and feedback from the AMIA community into the future.
Temporal- and concentration-dependent effects of transforming growth factor-beta 1 (TGF-β1) in primary human knee fibroblasts
Dilger, Oliver B., Carstens, Mason F. , Garrett, Daphne J., Berry, Daniel J., Thaler, Roman, Dudakovic, Amel , Berry, Daniel J. , Carstens, Mason , Sanchez-Sotelo, Joaquin, Berry, Daniel J , Berry, Daniel J., Sánchez‐Sotelo, Joaquín , Morrey, Mark E. , Abdel, Matthew P.

Bone & Joint Research | June 16, 2025 | Volume: 14 | Issue: 6 | Pages: 527-538

10.1302/2046-3758.146.bjr-2024-0387.r3 | PMID 40518918 Get It

AimsTo characterize the effects of varying experimental parameters of transforming growth factor-beta 1 (TGF-β1) in primary knee fibroblasts as an in vitro model of arthrofibrosis.MethodsPrimary knee fibroblasts were isolated from one patient undergoing primary total knee arthroplasty (TKA) and one patient undergoing revision TKA for arthrofibrosis, respectively. Fibroblasts were stimulated with varying concentrations and durations of the pro-fibrotic cytokine TGF-β1. Picrosirius red staining (PSR) was conducted to assess collagen deposition, and real-time quantitative polymerase chain reaction (RT-qPCR) and western blotting were performed to determine cellular gene expression levels. A collagen gel contraction assay was used to assess TGF-β1-induced fibroblast contraction.ResultsIn our experiments, TGF-β1-mediated collagen deposition was consistent across a vast concentration range (0.5 to 40 ng/ml). While α-smooth muscle actin (ACTA2) protein levels and SMAD2 phosphorylation were induced by low concentrations (1 ng/ml), robust ACTA2 transcription required higher concentrations (5 ng/ml) of TGF-β1. Evaluation of TGF-β1-mediated cell and cytoskeletal contractility shows that in the measured fibroblasts, this process occurs within three hours following TGF-β1 administration. Of note, TGF-β1-differentiated myofibroblasts exhibited greater contractile properties than naïve fibroblasts in the presence of TGF-β1.ConclusionTaken together, this study elucidates key TGF-β1 experimental parameters that will inform the development and interpretation of in vitro models of arthrofibrosis.Cite this article: Bone Joint Res 2025;14(6):527–538.
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium
Bettegowda, Chetan , Noushmehr, Houtan , Affinito, Alessandra , Ahluwalia, Manmeet S. , Ansorge, Olaf , Ayasoufi, Katayoun , Bagley, Stephen , Barnholtz‐Sloan, Jill S. , Brandsma, Dieta , Brodie, Chaya , Castro, Ana Valeria , Chang, Susan M. , Daher, Ahmad , Datta, Vineet , French, Pim J. , Golebiewska, Anna , Holdhoff, Matthias , LeBlang, Suzanne , Melin, Beatrice , Moulière, Florent , O’Leary, Claire , Robinson, Stephen , Sol, Nik , Vogelbaum, Michael A. , Walbert, Tobias , Watts, Colin , Wen, Patrick Y. , Wykes, Victoria , Yip, Stephen , Short, Susan , Barnholtz-Sloan, Jill S , Best, Myron , Brandsma, Dieta , Brüning-Richardson, Anke , Chang, Susan Marina , Condorelli, Gerolama , Daher, Ahmad , de Groot, John , French, Pim J , Galanis, Evanthia , Golebiewska, Anna , Hamerlik, Petra , Hanemann, C Oliver , Holdhoff, Matthias , Huse, Jason T. , Khasraw, Mustafa , LeBlang, Suzanne , Melin, Beatrice , Rominiyi, Ola , Roncaroli, F , Rudà, Roberta , Sol, Nik , van den Bent, Martin J , Walbert, Tobias , Watts, Colin , Weiss, Tobias , Weller, Michael , Wykes, Victoria , Yip, Stephen , Short, Susan C , Soffietti, Riccardo , Noushmehr, Houtan , Ayasoufi, Katayoun , Ahluwalia, Manmeet S , Bettegowda, Chetan , Groot, John de , Galanis, Evanthia , Hamerlik, Petra , Hanemann, C. Oliver , Khasraw, Mustafa , Rak, Janusz , Ray, Amitava, Roncaroli, Federico , Seoane, Joan , Bent, Martin J. van den , Wen, Patrick Yung , Soffietti, Riccardo

Neuro-Oncology | June 16, 2025 | Volume: 27 | Issue: 10 | Pages: 2496-2513

10.1093/neuonc/noaf140 | PMID 40884415 Get It

Abstract This review explores the pivotal role of preanalytical variables in bringing liquid biopsy approaches into the clinic for brain tumors. Preanalytical variables encompass a range of critical issues, from blood sample collection and handling to the impact of tumor heterogeneity and patient-specific factors. These variables introduce challenges such as false positives, false negatives, and variability in the analysis of tumor signals, which can hinder the diagnostic and prognostic utility of liquid biopsies. Understanding the nuances of preanalytical variables is essential for the successful implementation of liquid biopsy in clinical settings. This paper delves into strategies aimed at mitigating the influence of preanalytical variables by emphasizing the importance of standardized sample collection protocols, optimized sample processing and storage, quality control measures, and the integration of multiple liquid biopsy modalities.
Food seeking suppression by environmental enrichment accompanies cell type- and circuit-specific prelimbic cortical modulation
Agbude, Romarua, Steele, Oliver G. , Suto, Nobuyoshi , Peters, Kate Z. , Koya, Eisuke

No container title available | June 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.11.659116 | PMID 40661548 Get It

Abstract Cues such as fast-food advertisements associated with food can provoke food cravings which may lead to unhealthy overeating. To effectively control such cravings, we need to better understand the factors that reduce food cue reactivity and reveal corresponding ‘anti-craving’ brain mechanisms. We previously reported that access to environmental enrichment (EE) that provides cognitive and physical stimulation in mice reduced cue-evoked sucrose seeking and prelimbic cortex (PL) neuronal reactivity. To date, the phenotype of PL neurons that undergo EE-induced adaptations has not been fully elucidated. Therefore, we used brain slice electrophysiology to investigate how EE modulated intrinsic excitability in the general population of PL interneurons and pyramidal cells. Additionally, we used retrograde tracing and the neuronal activity marker ‘Fos’ to investigate how EE modulated cue-evoked recruitment of pyramidal cells projecting to the paraventricular nucleus of the thalamus (PVT) and nucleus accumbens core (NAc). Before the cue-evoked sucrose seeking test, EE enhanced the general, baseline excitability of inhibitory interneurons, but not pyramidal cells, thereby promoting inhibitory ‘overdrive’. During cue-evoked sucrose seeking, EE suppressed recruitment of PVT-, but not NAc-projecting, neurons thereby selectively promoting corticothalamic, but not corticoaccumbens, excitatory ‘underdrive’. Collectively, we further illuminate EE’s ‘anti-food seeking’ actions whereby EE promotes both cell type-specific (inhibitory interneuron ‘overdrive’) and circuit-specific (excitatory corticothalamic ‘underdrive’) neuroadaptations in the PL.
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis
Langford, Carol A. , Friedman, Marcia , Dehghan, Natasha, Gewurz‐Singer, Ora, Koening, Curry L. , Lin, Yih Chang, Moreland, Larry W. , Fifi‐Mah, Aurore , Forbess, Lindsy, Molloy, Eamonn, Yacyshyn, Elaine , McAlear, Carol A. , Burroughs, Cristina , Rhee, Rennie L. , Hajj‐Ali, Rula A. , Cuthbertson, David , Krischer, Jeffrey P. , Friedman, Marcia , Monach, Paul A , Specks, Ulrich , Spiera, Robert F , Yacyshyn, Elaine , Rhee, Rennie L , Jayne, David , Moreland, Larry W , Khalidi, Nader , Springer, Jason , Hellmich, Bernhard , Pagnoux, Christian , Monach, Paul A. , Flossmann, Oliver , Lanyon, Peter , Specks, Ulrich , Spiera, Robert , Jones, Rachel , Warrington, Kenneth J. , Jayne, David , Merkel, Peter A.

Arthritis & Rheumatology | June 12, 2025 | Volume: 77 | Issue: 12 | Pages: 1739-1748

10.1002/art.43272 | PMID 40506793 Get It

Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or equivalent), tapered and discontinued at week 12. Patients already taking methotrexate, azathioprine, mycophenolate, or leflunomide continued this medication at a stable dose. Patients achieving remission remained on their randomized assignment until relapse, early termination, or the common close date 12 months after enrollment of the last patient. Those who had a nonsevere relapse, had nonsevere worsening, or were not in remission by month 6 had the option to receive open‐label abatacept. The primary end point was the rate of treatment failure, defined as relapse, disease worsening, or failure to achieve a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0 or 1 by six months. Results Sixty‐five patients were randomized; 34 received abatacept and 31 received placebo. No statistical difference in the treatment failure rate was found between those who received abatacept and those who received placebo ( P = 0.853). Treatment with abatacept did not demonstrate any statistical difference from placebo in key secondary end points, including time to full remission (BVAS/WG = 0), duration of glucocorticoid‐free remission, relapse severity, prevention of damage, and patient‐reported quality‐of‐life outcomes. There was no difference in the frequency or severity of adverse events between treatment arms, including infection. Conclusion In patients with relapsing, nonsevere GPA, abatacept did not reduce the risk of relapse, severe worsening, or failure to achieve remission.
Measles vaccine attenuation comprises innate immune cell infection and interferon responses
Andres, Felix G M , Parusel, Sebastian, Siering, Oliver, Acosta, Francisco M. , Skeele, Dominic, Cattaneo, Roberto , Pfaller, Christian K. , Pfaller, Christian K , Ayasoufi, Katayoun , Sawatsky, Bevan

No container title available | June 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.09.657851 Get It

Abstract Measles virus (MeV) is a highly contagious pathogen capable of infecting immune cells and thereby causing immunosuppression and immune amnesia. A live-attenuated MeV vaccine is highly efficacious and has been safely administered for over 60 years. However, a detailed mechanistic understanding of the mode of its attenuation remains elusive. Here, we determined the molecular mechanisms underlying MeV vaccine attenuation in primary human immune cells. Enhanced infection of innate immune cells resulting in uncontrolled viral RNA synthesis and reduced ability to evade host antiviral responses induced a strong type-I interferon signature that arrested replication of the vaccine strain. In contrast, the wild type virus replicated slowly but steadily, avoiding detection by innate immunity.
Measuring artery diameter in rabbit angiograms for neurovascular disease modeling applications and device testing
Khan, YM , Franklin, J Ford, Bayraktar, Esref Alperen , Oliver, Alexander A , Ding, Yonghong , Lortscher, Sarah, Brinjikji, Waleed , Kadirvel, Ramanathan , Kallmes, David F. , Khan, Yasmine , Franklin, Jack , Bayraktar, Esref Alperen , Oliver, Alexander A , Ding, Yong-Hong , Lortscher, Sarah , Brinjikji, Waleed , Kadirvel, Ram , Kallmes, David F , Cortese, Jonathan

Interventional Neuroradiology | June 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251347398 | PMID 40491341 Get It

Background and purpose New Zealand White Rabbits are a useful preclinical model for neurovascular research. Inducing right common carotid artery aneurysms in New Zealand White Rabbits gives researchers the ability to test neurovascular devices in vivo. This study takes advantage of archived angiograms to obtain vascular measurements of interest for future research in rabbit models. Methods Rabbit angiograms from endovascular studies conducted in-house between 2005 and 2024 were analyzed using ImageJ at points of interest along the thoracic and abdominal aorta. Using scale references, the diameters of various New Zealand White Rabbit (2.5–3.5 kg) arteries were measured for aneurysm models and controls. Anatomic vascular variations were categorized and recorded. Results Measurable artery diameters at 39 points of interest were recorded for 170 female New Zealand White Rabbits. Type 1 vascular anatomy was the most common rabbit aortic arch, characterizing 85% of identifiable rabbit anatomies in this study. Conclusion By making these measurements available, this study simplifies future neurovascular studies, allowing for vasculature to be selected by size depending on the application. Additionally, the study offers insight into the relationship between elastase-induced aneurysms and surrounding vasculature size and draws size comparisons between some key arteries of interest.
Initial Surgeon Experiences With a Robotic-Assisted Cochlear Implant Electrode Array Insertion System
Ernst, Amanda R., Adunka, Oliver F., Carlson, Matthew L., Claussen, Alexander D. , Deep, Nicholas L. , Gantz, Bruce J. , Gantz, Jay A., Lee, Daniel J. , Patel, Neil S. , Yates, Charles W. , Hansen, Marlan R. , Nelson, Rick F , Babu, S., Carlson, Matthew L. , Gurgel, Richard Klaus , Hong, Robert , Hua, Xiaoyang , Santos, Felipe Oliveira dos

Otology & Neurotology | June 4, 2025 | Volume: 46 | Issue: 8 | Pages: 924-932

10.1097/mao.0000000000004554 | PMID 40466138 Get It

Objective To assess integration of a single-use robotic-assisted cochlear implant (RA-CI) electrode array insertion system into surgical workflows, identify potential challenges, and inform best practices. Study Design Survey. Setting Survey data from 16 surgeons across 10 US hospitals. Patients CI candidates 12 years and older with radiographically normal cochleae. Intervention CI surgery with single-use RA-CI insertion system during electrode array insertion. Main Outcome Measures Number of RA-CI to achieve proficiency, estimated additional time for RA-CI, and best practices to successfully incorporate the RA insertion system into CI surgery. Results A total of 121 RA-CI cases were performed. All surgeons completed the survey. Most surgeons (62.5%) reported they would feel comfortable using the device within five cases. Eight (50%) reported use of the RA system added 5 to 10 minutes to the case, and seven (44%) reported an added 10–15 minutes. Providing adequate incision size to secure the unit base superior to the temporal line and maximizing exposure of the facial recess were the most recommended best practices. Additional recommendations included pulling the receiver/stimulator forward within the pocket to facilitate a full electrode array insertion and considering drive head placement and mastoidectomy size to maximize overall visibility during electrode array insertion. Conclusions Proficiency with an RA electrode array insertion system during CI surgery can be achieved with minor adjustments to the surgical approach, within relatively few use cases (generally <5) and with minimal time addition (between 5 and 15 min). Training to specific best practices is important before initial clinical use.